MEET OUR TEAM
Our Leadership Team
-
Richard M. Silver, M.D.
CO-FOUNDER
CHIEF EXECUTIVE OFFICERDr. Silver is a Distinguished University Professor and Director of the SmartState Center for Inflammation and Fibrosis Research at the Medical University of South Carolina, specializing in scleroderma and scleroderma lung disease, and has pioneered advancements in clinical care and research of systemic sclerosis.
-
Galina S. Bogatkevich, M.D. Ph.D.
CO-FOUNDER
CHIEF SCIENTIFIC OFFICERDr. Bogatkevich is an Associate Professor in the Division of Rheumatology and Immunology at the Medical University of South Carolina, with extensive experience in pharmacology, cell and molecular biology, and specific expertise in the pathogenesis of systemic sclerosis and fibrosis models.
-
Timothy P. M. Whelan, M.D.
DIRECTOR, ILD PROGRAM
Dr. Whelan is a Professor of Medicine and Medical Director of the Lung Transplant Program at MUSC, specializing in advanced lung disease and transplants, with over 20 years of experience in clinical trials for pulmonary fibrosis therapies.
Scientific Advisory Committee
-
Robert A. Blouin, Pharm.D.
Dr. Blouin is the President and CEO of Med Aditus International and Emeritus Distinguished Professor at UNC Chapel Hill, where he also served as Executive Vice Chancellor and Provost. With over 35 years of research in pharmacokinetics, drug metabolism, and toxicology, he has played a pivotal role in academic drug discovery, particularly in cancer and rare disease therapeutics. Dr. Blouin will apply his expertise to advancing M10 as an antifibrotic treatment.
-
Lawrence Olanoff, M.D., Ph.D.
Dr. Olanoff is an adjunct Assistant Professor and and Executive in Residence at the Medical University of South Carolina. During his pharmaceutical development career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas.
-
Perry Halushka, Ph.D., M.D.
Dr. Halushka is a Distinguished University Professor of Cell and Molecular Pharmacology and dean emeritus of the College of Graduate Studies at MUSC. Dr. Halushka is a clinical pharmacologist consulting big pharma and startup companies for almost 40 years. He will provide his expertise for the various aspects of the development of M10 as an antifibrotic medication.
-
Anthony J. Hickey, Ph.D., DSc.
Dr. Hickey is Professor Emeritus of Pharmacoengineering and Molecular Pharmaceutics of the Eshelman School of Pharmacy and Adjunct Professor at UNC Chapel Hill. He is a Fellow of the American Association for the Advancement of Science, American Association of Pharmaceutical Scientists, Academy of Pharmaceutical Sciences of Great Britain, the Royal Society of Biology, Royal Society of Medicine and National Academy of Inventors.
-
Carol Feghali-Bostwick, Ph.D.
Dr. Feghali-Bostwick is the SmartState and Kitty Trask Holt Endowed Chair for Scleroderma Research and Distinguished University Professor at the Medical University of South Carolina. She is an internationally recognized translational researcher and expert in dermal fibrosis with a focus on developing new anti-fibrotic strategies for scleroderma and other fibrosing conditions.
-
Gary Gilkeson, M.D.
Dr. Gilkeson, a Distinguished University Professor in the Division of Rheumatology & Immunology at the Medical University of South Carolina, brings extensive expertise as a clinician, translational immunologist, and bench scientist. He will serve as a consultant on immunologic aspects of the project, contributing his knowledge in preclinical therapeutic development.